pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
467
stories
Jul 29, 26
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
biospace
Jul 29, 26
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
endpoints
Jul 29, 26
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
Jul 29, 26
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
Jul 28, 26
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
biospace
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
Jul 27, 26
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
Jul 27, 26
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 27, 26
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
Jul 27, 26
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
Jul 24, 26
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 24, 26
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
fiercebiotech
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
endpoints
Jul 22, 26
Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer
stat
Jul 22, 26
From Big Pharma to specialty: why moving closer to the patient changes everything
biospace
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 21, 26
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
endpoints
Jul 21, 26
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
biospace
Jul 21, 26
Crystalys mines $130M series B to push gout drug through phase 3
fiercebiotech
Jul 21, 26
STAT+: Anthropic deepens work with rare disease drugs
stat
Jul 21, 26
STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
stat
Jul 21, 26
Agios says adios to sickle cell program over lackluster phase 2 data
fiercebiotech
Jul 20, 26
STAT+: The next step of site-neutral, and a fiery PBM hearing
stat
Jul 20, 26
STAT+: A most-wanted fugitive appears to have been secretly working as a biotech executive
stat
← prev
page 9 of 16
next →
